Combination of chemotherapy and dual-targeted treatments Phase III Breakwater Clinical trials supported for BRAF-mutated metastatic colorectal cancer FDA approval

breakwater trial representation

Data from this 28-country multi-institutional effort helped the Food and Drug Administration (FDA) approve this combination more quickly in December 2024, giving patients with BRAF V600E-mutant mCRC a new and effective first-line treatment choice.

A Neutralizing Antibody for Inhibitory Factors in Nerve Regeneration Promotes Improved Motor Function

antibody nerve regeneration representation

The recovery process for patients with acute spinal cord injuries can be enhanced by antibodies. This has been studied with encouraging results by researchers at 13 clinics in Germany, Switzerland, the Czech Republic, and Spain. For the first time, patient groups exhibiting a treatment impact that was clinically relevant could be identified. December 2024 will see the start of a follow-up study.